NEW YORK, Sept. 27, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Dr. Reddy’s Laboratories Ltd. ("Dr. Reddy’s") (NYSE:RDY) between June 17, 2015 and August 10, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/plsra-c/dr-reddys-laboratories-ltd?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India.
If you suffered a loss in Dr. Reddy’s you have until October 24, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 



